转移性肾细胞癌初始减瘤性肾切除术与初始靶向治疗的生存比较
该研究基于美国国家癌症数据库2006至2013年诊断为转移性肾细胞癌的15,068例患者,比较初始减瘤性肾切除术与初始靶向治疗的总生存。逆概率加权分析显示初始减瘤性肾切除术组中位总生存16.5个月,优于初始靶向治疗组的9.2个月(HR 0.61,95%CI 0.59-0.64,p<0.001)。
要点
- 初始减瘤性肾切除术后6个月48.0%患者接受靶向治疗,其中15.3%在靶向治疗前死亡。
- 初始靶向治疗后6个月4.7%患者接受减瘤性肾切除术,其中44.9%在手术前死亡。
- 逆概率加权后初始减瘤性肾切除术与更好的总生存相关(中位16.5 vs 9.2个月)。
核心结论
- 在合适的手术候选者中,这些数据支持将减瘤性肾切除术作为转移性肾细胞癌的初始治疗方式。
研究设计与样本
- 研究评估了美国国家癌症数据库2006至2013年诊断为转移性肾细胞癌并接受减瘤性肾切除术和/或靶向治疗的病例记录。
- 共纳入15,068例患者,其中6,731例接受初始减瘤性肾切除术,8,337例接受初始靶向治疗。
- 采用竞争风险分析评估后续治疗,并用逆概率治疗加权(基于倾向性)校正治疗选择偏倚,通过Kaplan-Meier分析和Cox比例风险回归比较总生存。
主要发现
- 初始减瘤性肾切除术后6个月,48.0%的患者接受靶向治疗,其中15.3%在初始减瘤性肾切除术后、靶向治疗前死亡。
- 初始靶向治疗后6个月,4.7%的患者接受减瘤性肾切除术,其中44.9%在初始靶向治疗后、减瘤性肾切除术前死亡。
- 初始减瘤性肾切除术(OR 2.02,95%CI 1.69-2.43,p<0.001)和初始靶向治疗后的减瘤性肾切除术(HR 2.6,95%CI 1.69-4.01,p<0.001)在学术机构比社区机构更可能实施。
- 逆概率治疗加权分析显示,初始减瘤性肾切除术与初始靶向治疗相比,中位总生存分别为16.5个月和9.2个月(HR 0.61,95%CI 0.59-0.64,p<0.001)。
关键数值与推荐
- 初始减瘤性肾切除术组中位总生存16.5个月,初始靶向治疗组9.2个月(HR 0.61,95%CI 0.59-0.64,p<0.001)。
- 初始减瘤性肾切除术后6个月48.0%接受靶向治疗,其中15.3%在靶向治疗前死亡。
- 初始靶向治疗后6个月4.7%接受减瘤性肾切除术,其中44.9%在手术前死亡。
临床怎么用
- 对于合适的手术候选者,可考虑将减瘤性肾切除术作为转移性肾细胞癌的初始治疗策略。
- 需注意初始减瘤性肾切除术后部分患者可能因死亡而无法接受后续靶向治疗。
- 学术机构更常实施减瘤性肾切除术,临床决策时可结合机构经验。
局限性
- 研究为回顾性数据库分析,尽管采用逆概率治疗加权,仍可能存在未测量的混杂因素。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The optimal sequence of cytoreductive nephrectomy and targeted therapy of metastatic renal cell carcinoma is unclear. We compared overall survival between patients with metastatic renal cell carcinoma treated with initial cytoreductive nephrectomy with or without subsequent targeted therapy vs initial targeted therapy with or without subsequent cytoreductive nephrectomy. MATERIALS AND METHODS: We evaluated the records of cases in the National Cancer Database diagnosed with metastatic renal cell carcinoma between 2006 and 2013 who were treated with cytoreductive nephrectomy and/or targeted therapy. Receipt of targeted therapy after initial cytoreductive nephrectomy and cytoreductive nephrectomy after initial targeted therapy were evaluated on competing risks analyses. To account for treatment selection bias, inverse probability of treatment weighting was performed based on the propensity to receive initial cytoreductive nephrectomy or initial targeted therapy. Overall survival was compared between the groups by Kaplan-Meier analysis and Cox proportional hazards regression. RESULTS: Of the 15,068 patients included in study 6,731 underwent initial cytoreductive nephrectomy and 8,337 received initial targeted therapy. Six months after initial cytoreductive nephrectomy 48.0% of patients received targeted therapy, of whom 15.3% died after initial cytoreductive nephrectomy prior to targeted therapy. Six months after initial targeted therapy 4.7% of patients underwent cytoreductive nephrectomy, of whom 44.9% died after initial targeted therapy prior to cytoreductive nephrectomy. Initial cytoreductive nephrectomy (OR 2.02, 95% CI 1.69-2.43, p <0.001) and cytoreductive nephrectomy after initial targeted therapy (HR 2.6, 95% CI 1.69-4.01, p <0.001) were more likely to be performed at academic vs community institutions. On inverse probability of treatment weighting analysis initial cytoreductive nephrectomy was associated with improved overall survival compared to initial targeted therapy (median 16.5 vs 9.2 months, HR 0.61, 95% CI 0.59-0.64, p <0.001). CONCLUSIONS: Given the greater likelihood of receiving multimodal therapy and the associated overall survival benefit, these data support cytoreductive nephrectomy as the initial approach to metastatic renal cell carcinoma in appropriate surgical candidates. Continued efforts are warranted to establish the optimal multimodal approach in these patients.
引用
- Bhindi B, Habermann EB, Mason RJ, et al. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma. J Urol. 2018. PMID: 29574109. doi:10.1016/j.juro.2018.03.077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。